Solicitation of Nominations for Appointment to the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 23424-23425 [2023-07997]
Download as PDF
<![CDATA[
23424
Federal Register / Vol. 88, No. 73 / Monday, April 17, 2023 / Notices
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than May 15, 2023.
A. Federal Reserve Bank of Boston
(Eileen Leighton, Vice President) 600
Atlantic Avenue, Boston, Massachusetts
02210—02204; or by email to
BOS.SRC.Applications.Comments@
bos.frb.org:
1. Newburyport Five Cents Bancorp,
MHC, and its wholly-owned subsidiary,
Newburyport Five Cents Bancorp, Inc.,
both of Newburyport, Massachusetts; to
merge with Pentucket Bank Holdings,
MHC, and Pentucket Bancorp, Inc.,
respectively, and thereby indirectly
acquire Pentucket Bank, all of Haverhill,
Massachusetts.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–07940 Filed 4–14–23; 8:45 am]
lotter on DSK11XQN23PROD with NOTICES1
BILLING CODE P
VerDate Sep<11>2014
16:57 Apr 14, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the CDC/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS), is seeking nominations
for membership on the CDC/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment (CHAC). CHAC consists of 18
experts in fields associated with public
health, epidemiology, laboratory
practice, immunology, infectious
diseases, substance use disorder,
behavioral science, health education,
healthcare delivery, state health
programs, clinical care, preventive
health, medical education, health
services and clinical research, health
equity, and healthcare financing, who
are selected by the Secretary, HHS.
DATES: Nominations for membership on
CHAC must be received no later than
October 1, 2023. Packages received after
this time will not be considered for the
current membership cycle.
ADDRESSES: All nominations should be
emailed to nchhstppolicy@cdc.gov with
the subject line ‘‘CHAC 2024
Nomination.’’
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Marah Condit, MS, Committee
Management Lead, Office of Policy,
Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027. Telephone: (404)
639–3423; Email: MCondit@cdc.gov.
SUPPLEMENTARY INFORMATION: The
Secretary, Department of Health and
Human Services (HHS), and by
delegation the Director, Centers for
Disease Control and Prevention (CDC),
and the Administrator, Health
Resources and Services Administration
(HRSA), are authorized by the Public
Health Service Act to: (1) conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases and other impairments; (2)
assist states and their political
subdivisions in preventing, suppressing,
and treating communicable diseases and
other preventable conditions and in
promoting health and well-being; (3)
assist public and non-profit private
entities in preventing, controlling, and
treating sexually transmitted diseases
(STDs), including the human
immunodeficiency virus (HIV); (4)
improve health and achieve health
equity through access to quality services
and a skilled health workforce and
innovative programs; (5) support
healthcare services to persons with or
who experience risk for HIV, viral
hepatitis, and other STDs; (6) advance
the education of health professionals
and the public about HIV, viral
hepatitis, and other STDs; and (7)
adolescent and school health as it
pertains to HIV, viral hepatitis, and
STDs.
The CDC/HRSA Advisory Committee
on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC)
meets at least two times each calendar
year, or at the discretion of the
Designated Federal Officers in
consultation with the CHAC co-chairs.
HHS policy stipulates that committee
membership be balanced in terms of
points of view represented and the
committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. The CHAC
charter stipulates that the Committee
must include at least four members who
are persons with HIV. The Committee
may also include representation from
persons with lived experience, such as
those who have experienced viral
hepatitis, STDs, and drug use; state and
local health and education agencies;
HIV/viral hepatitis/STD communitybased organizations; and the ethics or
faith-based community.
Committee members are Special
Government Employees (SGEs),
requiring the filing of financial
disclosure reports at the beginning of
E:\FR\FM\17APN1.SGM
17APN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 73 / Monday, April 17, 2023 / Notices
and annually during their terms.
Individuals who are selected for
appointment will be required to provide
detailed information regarding their
financial interests and, for example, any
work they do for the federal government
through research grants or contracts.
Disclosure of this information is
required in order for CDC ethics officials
to determine whether there is a conflict
between the SGE’s public duties as a
member of CHAC and the SGE’s private
interests, including an appearance of a
loss of impartiality as defined by federal
laws and regulations, and to identify
any required remedial action needed to
address the potential conflict.
CDC and HRSA review potential
candidates for CHAC membership when
a vacancy arises and provide a slate of
nominees for consideration to the
Secretary of HHS for final selection.
CDC and HRSA each publish a Federal
Register notice and will be using a joint
process to nominate nominees on a
rolling basis; thus, applications received
by CDC will be shared with HRSA for
consideration. Therefore, potential
candidates need only apply in response
to one of the Federal Register notices.
HHS notifies selected candidates of
their appointment near the start of the
term in December 2024, or as soon as
the HHS selection process is completed.
Note that the need for different expertise
varies from year to year and a candidate
who is not selected in one year may be
reconsidered in a subsequent year.
Candidates should submit the following
items:
D A letter of interest or personal
statement from the nominee stating
how the nominee’s expertise would
inform the work of CHAC
D A biographical sketch of the nominee
(500 words or fewer)
D Current curriculum vitae or resume,
including complete contact
information (telephone numbers,
mailing address, and email address)
D At least one letter of recommendation
from person(s) not employed by HHS.
Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be
submitted by a person not employed
by an HHS agency (i.e., CDC, National
Institutes of Health, Food and Drug
Administration, etc.).
Nominations may be submitted
directly by the individual seeking
nomination or by the person/
organization recommending the
candidate. CDC and HRSA will collect
and retain nominations received for up
to two years to create a pool of potential
CHAC nominees.
VerDate Sep<11>2014
16:57 Apr 14, 2023
Jkt 259001
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–07997 Filed 4–14–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–23–1294]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘The Maternal
Mortality Review Information
Application (MMRIA)’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on January
11, 2023 to obtain comments from the
public and affected agencies. CDC
received one comment related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
23425
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
The Maternal Mortality Review
Information Application (MMRIA)
(OMB Control No. 0920–1294, Exp. 04/
30/2023)—Revision—National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) seeks a Revision to
continue to collect information through
the Maternal Mortality Review
Information Application (MMRIA) for
three additional years. MMRIA is a
standardized data collection system that
allows Maternal Mortality Review
Committees (MMRCs) across the
country to abstract relevant data
(clinical and non-clinical) from a variety
of sources, document committee
decisions, and analyze data in order to
better understand the contributing
factors and preventability of pregnancyrelated deaths and thus to develop
recommendations for prevention.
Pregnancy-related deaths are defined
as a death as a result of pregnancy or
delivery complications, a chain of
events initiated by pregnancy, or the
aggravation of an unrelated condition by
the physiologic effects of pregnancy.
Considerable racial disparities exist,
with persons who are non-Hispanic
Native Hawaiian or Other Pacific
Islander, non-Hispanic American
Indian/Alaska Native and non-Hispanic
E:\FR\FM\17APN1.SGM
17APN1
]]>Agencies
[Federal Register Volume 88, Number 73 (Monday, April 17, 2023)]
[Notices]
[Pages 23424-23425]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07997]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the CDC/HRSA
Advisory Committee on HIV, Viral Hepatitis and STD Prevention and
Treatment
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), within
the Department of Health and Human Services (HHS), is seeking
nominations for membership on the CDC/HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and Treatment (CHAC). CHAC consists
of 18 experts in fields associated with public health, epidemiology,
laboratory practice, immunology, infectious diseases, substance use
disorder, behavioral science, health education, healthcare delivery,
state health programs, clinical care, preventive health, medical
education, health services and clinical research, health equity, and
healthcare financing, who are selected by the Secretary, HHS.
DATES: Nominations for membership on CHAC must be received no later
than October 1, 2023. Packages received after this time will not be
considered for the current membership cycle.
ADDRESSES: All nominations should be emailed to [email protected]
with the subject line ``CHAC 2024 Nomination.''
FOR FURTHER INFORMATION CONTACT: Marah Condit, MS, Committee Management
Lead, Office of Policy, Planning, and Partnerships, National Center for
HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6, Atlanta,
Georgia 30329-4027. Telephone: (404) 639-3423; Email: [email protected].
SUPPLEMENTARY INFORMATION: The Secretary, Department of Health and
Human Services (HHS), and by delegation the Director, Centers for
Disease Control and Prevention (CDC), and the Administrator, Health
Resources and Services Administration (HRSA), are authorized by the
Public Health Service Act to: (1) conduct, encourage, cooperate with,
and assist other appropriate public health authorities, scientific
institutions, and scientists in the conduct of research,
investigations, experiments, demonstrations, and studies relating to
the causes, diagnosis, treatment, control, and prevention of physical
and mental diseases and other impairments; (2) assist states and their
political subdivisions in preventing, suppressing, and treating
communicable diseases and other preventable conditions and in promoting
health and well-being; (3) assist public and non-profit private
entities in preventing, controlling, and treating sexually transmitted
diseases (STDs), including the human immunodeficiency virus (HIV); (4)
improve health and achieve health equity through access to quality
services and a skilled health workforce and innovative programs; (5)
support healthcare services to persons with or who experience risk for
HIV, viral hepatitis, and other STDs; (6) advance the education of
health professionals and the public about HIV, viral hepatitis, and
other STDs; and (7) adolescent and school health as it pertains to HIV,
viral hepatitis, and STDs.
The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC) meets at least two times each calendar
year, or at the discretion of the Designated Federal Officers in
consultation with the CHAC co-chairs.
HHS policy stipulates that committee membership be balanced in
terms of points of view represented and the committee's function.
Appointments shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, gender identity, HIV
status, disability, and cultural, religious, or socioeconomic status.
Nominees must be U.S. citizens and cannot be full-time employees of the
U.S. Government. Current participation on federal workgroups or prior
experience serving on a federal advisory committee does not disqualify
a candidate; however, HHS policy is to avoid excessive individual
service on advisory committees and multiple committee memberships. The
CHAC charter stipulates that the Committee must include at least four
members who are persons with HIV. The Committee may also include
representation from persons with lived experience, such as those who
have experienced viral hepatitis, STDs, and drug use; state and local
health and education agencies; HIV/viral hepatitis/STD community-based
organizations; and the ethics or faith-based community.
Committee members are Special Government Employees (SGEs),
requiring the filing of financial disclosure reports at the beginning
of
[[Page 23425]]
and annually during their terms. Individuals who are selected for
appointment will be required to provide detailed information regarding
their financial interests and, for example, any work they do for the
federal government through research grants or contracts. Disclosure of
this information is required in order for CDC ethics officials to
determine whether there is a conflict between the SGE's public duties
as a member of CHAC and the SGE's private interests, including an
appearance of a loss of impartiality as defined by federal laws and
regulations, and to identify any required remedial action needed to
address the potential conflict.
CDC and HRSA review potential candidates for CHAC membership when a
vacancy arises and provide a slate of nominees for consideration to the
Secretary of HHS for final selection. CDC and HRSA each publish a
Federal Register notice and will be using a joint process to nominate
nominees on a rolling basis; thus, applications received by CDC will be
shared with HRSA for consideration. Therefore, potential candidates
need only apply in response to one of the Federal Register notices. HHS
notifies selected candidates of their appointment near the start of the
term in December 2024, or as soon as the HHS selection process is
completed. Note that the need for different expertise varies from year
to year and a candidate who is not selected in one year may be
reconsidered in a subsequent year. Candidates should submit the
following items:
[ssquf] A letter of interest or personal statement from the nominee
stating how the nominee's expertise would inform the work of CHAC
[ssquf] A biographical sketch of the nominee (500 words or fewer)
[ssquf] Current curriculum vitae or resume, including complete contact
information (telephone numbers, mailing address, and email address)
[ssquf] At least one letter of recommendation from person(s) not
employed by HHS. Candidates may submit letter(s) from current HHS
employees if they wish, but at least one letter must be submitted by a
person not employed by an HHS agency (i.e., CDC, National Institutes of
Health, Food and Drug Administration, etc.).
Nominations may be submitted directly by the individual seeking
nomination or by the person/organization recommending the candidate.
CDC and HRSA will collect and retain nominations received for up to two
years to create a pool of potential CHAC nominees.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-07997 Filed 4-14-23; 8:45 am]
BILLING CODE 4163-18-P
